secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2026-08-06T11:04:02+00:00
Accession:  0001193125-26-336681
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q2 2026 net loss $43.4M; cash $626M; MRT-8102 GFORCE-1 readout H2 2026
--------------------------------------------------------------------------------

- Net loss of $43.4M in Q2 2026 vs $12.3M in Q2 2025; collaboration revenue $9.0M vs $23.2M.
- Cash, equivalents, and marketable securities $626.0M as of June 30, 2026; expected to fund operations into 2029.
- MRT-8102 GFORCE-1 study fully enrolled; readout of CRP and calprotectin data expected H2 2026.
- Novartis activated Phase 2 study of MRT-6160 (DDY391) in Sjögren's disease; Monte Rosa eligible for milestone.
- MODeFIRe-1 Phase 2 study of MRT-2359 in mCRPC with AR mutations activated; first patient dosing expected Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/0001193125-26-336681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer